Slamon DJ - Search Results

1

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. O'Brien NA, et al. Among authors: slamon dj. Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8. Breast Cancer Res. 2020. PMID: 32795346 Free PMC article.

2

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

3

Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Pietras RJ, et al. Among authors: slamon dj. Cancer Res. 1999 Mar 15;59(6):1347-55. Cancer Res. 1999. PMID: 10096569

4

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. Arboleda MJ, et al. Among authors: slamon dj. Cancer Res. 2003 Jan 1;63(1):196-206. Cancer Res. 2003. PMID: 12517798

5

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Konecny GE, et al. Among authors: slamon dj. Cancer Res. 2006 Feb 1;66(3):1630-9. doi: 10.1158/0008-5472.CAN-05-1182. Cancer Res. 2006. PMID: 16452222

6

HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.

Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ. Wilson CA, et al. Among authors: slamon dj. Breast Cancer Res. 2005;7(6):R1058-79. doi: 10.1186/bcr1343. Epub 2005 Nov 8. Breast Cancer Res. 2005. PMID: 16457687 Free PMC article.

7

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Finn RS, et al. Among authors: slamon dj. Breast Cancer Res Treat. 2007 Nov;105(3):319-26. doi: 10.1007/s10549-006-9463-x. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268817

8

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. Britten CD, et al. Among authors: slamon dj. Clin Breast Cancer. 2009 Feb;9(1):16-22. doi: 10.3816/CBC.2009.n.003. Clin Breast Cancer. 2009. PMID: 19299235 Free PMC article. Clinical Trial.

9

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. Finn RS, et al. Among authors: slamon dj. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419. Breast Cancer Res. 2009. PMID: 19874578 Free PMC article.

10

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.

Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ. Konecny GE, et al. Among authors: slamon dj. Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4. Breast Cancer Res Treat. 2010. PMID: 20130985

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters